Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination viaIn VivoPharmacodynamic Evaluation against Candida glabrata with and withoutfksMutations

Antifungal Susceptibility Testing of a 10-year Collection ofCandidaspp. Isolated from Patients with Candidemia

(2014) R. Iatta et al.   JOURNAL OF CHEMOTHERAPY

DifferentialIn VivoActivities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and withoutFKSResistance Mutations

(2012) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials

(2012) D. R. Andes et al.   CLINICAL INFECTIOUS DISEASES

Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata

(2012) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study

(2012) A. F. Schmalreck et al.   MYCOSES

Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia

(2011) David Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria

(2011) M.A. Pfaller et al.   DRUG RESISTANCE UPDATES

Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009)

(2011) Michael A. Pfaller et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Fitness and Virulence Costs of Candida albicans FKS1 Hot Spot Mutations Associated With Echinocandin Resistance

(2011) Ronen Ben-Ami et al.   JOURNAL OF INFECTIOUS DISEASES

Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains

(2010) M. Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

FKS2Mutations Associated with Decreased Echinocandin Susceptibility ofCandida glabratafollowing Anidulafungin Therapy

(2010) Sofia Costa-de-Oliveira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

FKS Mutations and Elevated Echinocandin MIC Values among Candida glabrata Isolates from U.S. Population-Based Surveillance

(2010) A. J. Zimbeck et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species

(2010) D. Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species

(2010) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Epidemiology of Invasive Mycoses in North America

(2010) Michael A. Pfaller et al.   CRITICAL REVIEWS IN MICROBIOLOGY

Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008–2009)

(2010) Michael A. Pfaller et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Breakthrough Invasive Candidiasis in Patients on Micafungin

(2010) C. D. Pfeiffer et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)

(2010) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrata Bloodstream Isolates Serially Obtained from a Hematopoietic Stem Cell Transplant Recipient

(2009) F. Chapeland-Leclerc et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3- -D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint

(2009) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review

(2009) Hsin-Yun Sun et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Caspofungin-non-susceptible Candida isolates in cancer patients

(2009) D. P. Kofteridis et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins andCandidaspp.

(2009) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007

(2009) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment

(2008) J. D. Cleary et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia

(2008) J. W. Baddley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection

(2008) G. R. Thompson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model

(2008) D. R. Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population pharmacokinetics of micafungin in adult patients

(2007) Tawanda Gumbo et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE